Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission

Cancer

Volumn 120, Issue 14, 2014, Pages 2122-2129

  Pingali, Sai Ravi ^a   Jewell, Sarah W ^b   Havlat, Luiza ^c   Bast, Martin A ^c   Thompson, Jonathan R ^a   Eastwood, Daniel C ^a   Bartlett, Nancy L ^b   Armitage, James O ^c   Wagner Johnston, Nina D ^b   Vose, Julie M ^c   Fenske, Timothy S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

first complete remission; Hodgkin lymphoma; Limited utility; routine surveillance imaging

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLASSICAL HODGKIN LYMPHOMA; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; COMPARATIVE STUDY; ECONOMICS; HEALTH CARE COST; HEALTH SURVEY; HODGKIN DISEASE; INDUCTION CHEMOTHERAPY; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; UNITED STATES; UTILIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CAUSE OF DEATH; DACARBAZINE; DIRECT SERVICE COSTS; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; VINBLASTINE;

EID: 84903791210     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28698     Document Type: Article

References (32)

1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2010 [based on the November 2012 SEER data submission, posted to the SEER web site April 2013]. Bethesda, MD: National Cancer Institute; 2013.
2. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001. Patient and Tumor Characteristics. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute, SEER Program; 2007.
3. Hoppe RT, Advani RH, Ai WZ, et al. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. Available at: www.nccn.org/. Accessed August 30, 2013.
4. Voss SD, Chen L, Constine LS, et al. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 2635-2640.
5. Radford JA, Eardley A, Woodman C, Crowther D,. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997; 314: 343-346. (Pubitemid 27056556)
6. Dryver ET, Jernstrom H, Tompkins K, Buckstein R, Imrie KR,. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer. 2003; 89: 482-486. (Pubitemid 37026429)
7. Torrey MJ, Poen JC, Hoppe RT,. Detection of relapse in early stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 1997; 15: 1123-1130. (Pubitemid 27106298)
8. Brenner DJ, Hall EJ,. Computed tomography-an increasing source of radiation exposure. N Engl J Med. 2007; 357: 2277-2284. (Pubitemid 350190758)
9. Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology. 2009; 251: 175-184.
10. Cheson BD,. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011; 29: 1844-1854.
11. Thompson CA, Charlson ME, Schenkein E, et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol. 2010; 21: 2262-2266.
12. Wagner-Johnston ND, Bartlett NL,. Role of routine imaging in lymphoma. J Natl Compr Canc Netw. 2011; 9: 575-584; quiz 585.
13. Hollander M, Wolfe D A,. Nonparametric Statistical Methods. Hoboken, NJ: John Wiley & Sons, Inc.; 1999.
14. Gray R,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
15. Agresti A,. Categorical Data Analysis Hoboken, NJ: John Wiley & Sons, Inc.; 1990.
16. Kaplan EL, Meier P,. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 282: 457-481.
17. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586. (Pubitemid 350002966)
18. Eichenauer DA, Engert A, Dreyling M, Group EGW,. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22 (suppl 6): vi55-vi58.
19. Gerber TC, Carr JJ, Arai AE, et al. Ionizing radiation in cardiac imaging: a science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation. 2009; 119: 1056-1065.
20. Hall EJ, Brenner DJ,. Cancer risks from diagnostic radiology. Br J Radiol. 2008; 81: 362-378. (Pubitemid 351743850)
21. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK,. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol. 2006; 24: 4116-4122. (Pubitemid 46622287)
22. Patel V, Buckstein M, Perini R, Hill-Kayser C, Svoboda J, Plastaras JP,. Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective. Leuk Lymphoma. 2013; 54: 2168-2176.
23. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013; 31: 684-691.
24. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P,. ABVD plus subtotal nodal versus involved-field radiotherapy in early stage Hodgkin's disease: long-term results. J Clin Oncol. 2004; 22: 2835-2841. (Pubitemid 41079901)
25. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006; 91: 475-481.
26. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007; 25: 3746-3752. (Pubitemid 47372616)
27. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010; 51: 1337-1343.
28. Press O, LeBlanc M, Rimsza L,. A phase II trial of response adapted therapy of stages III-IV Hodgkin lymphoma using early interim FDG-PET imaging: US Intergroup S0816 [abstract]. Hematol Oncol. 2013; 31: 137.
29. Dann EJ, Berkahn L, Mashiach T, et al. Hodgkin lymphoma in first remission: routine PET/CT imaging is not superior to clinical follow-up for patients without residual mass: results of a bi-national study including 368 patients [abstract]. Blood. 2013; 122: 2995.
30. Berrington de Gonzalez A, Darby S,. Risk of cancer from diagnostic x-rays: estimates for the UK and 14 other countries. Lancet. 2004; 363: 345-351. (Pubitemid 38169539)
31. National Research Council. Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII, Phase 2. Washington, DC: The National Academies Press; 2006.
32. Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR,. Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin Lymphoma Myeloma Leuk. 2010; 10: 270-277.